Table 5.
The effects of treatment type on DAS28 score and treatment target (low disease activity and remission)
| Patientsa | Mean DAS28 score (SD) | p value | Remission + LDA rate (%) | p value | |
|---|---|---|---|---|---|
| bDMARD therapy | 412 (total) | ||||
| bDMARD monotherapy | 56 | 4.8 (1.8) | 0.0108 | 21.4 | 0.507 |
| bDMARD combination therapy | 356 | 4.3 (1.5) | 25.6 | ||
| bDMARD monotherapy | 56 (total) | ||||
| TNF inhibitorsb | 49 | 5.0 (1.7) | 0.0479 | 16.3 | 0.0317 |
| Tocilizumab | 7 | 3.6 (2.1) | 57.1 | ||
| TNF inhibitorsb | 327 | ||||
| Monotherapy | 49 | 5.0 (1.7) | 0.0012 | ||
| Combination therapy | 278 | 4.3 (1.4) | |||
| Tocilizumab | 85 | ||||
| Monotherapy | 7 | 3.6 (2.1) | 0.2672 | ||
| Combination therapy | 78 | 4.3 (1.6) |
aNumber of patients with available score data
bTNF inhibitors include infliximab, adalimumab, and etanercept